China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives
You may also be interested in...
Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China
SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6
Hutchison Medipharma Initiates Phase I Trials Of Cancer-fighting Candidate Sulfatinib In China
SHANGHAI - Chinese innovative drug developer Hutchison MediPharma has initiated Phase I clinical trials in China for its anti-cancer drug candidate, HMPL-012 (sulfatinib), the company said May 6
China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints
SHANGHAI - Chinese biotech Hutchison MediPharma announced Nov. 5 that its Phase IIb global clinical trial of lead candidate HMPL-004 in patients with ulcerative colitis, a form of inflammatory bowel disease, met primary and key secondary endpoints